Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 99.8% in August

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 16 shares, a decline of 99.8% from the July 30th total of 9,551 shares. Based on an average daily volume of 322,731 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Oncotelic Therapeutics Stock Performance

OTCMKTS:OTLC opened at $0.03 on Thursday. The company’s 50-day moving average is $0.04 and its two-hundred day moving average is $0.04. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.08 and a quick ratio of 0.08. The firm has a market capitalization of $14.24 million, a price-to-earnings ratio of 0.05 and a beta of -0.23.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.